Idioma:

New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia

Moorman, Anthony V

Haematologica (Roma), 2016-04, Vol.101 (4), p.407-416 [Periódico revisado por pares]

Italy: Ferrata Storti Foundation

Texto completo disponível

Citações Citado por

Enviar para

Título:
New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia
Autor: Moorman, Anthony V
Assuntos: Antineoplastic Agents - therapeutic use ; B-Lymphocytes - drug effects ; B-Lymphocytes - metabolism ; B-Lymphocytes - pathology ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Chromosomes, Human, Pair 12 ; Chromosomes, Human, Pair 21 ; Chromosomes, Human, Pair 22 ; Chromosomes, Human, Pair 9 ; Dasatinib - therapeutic use ; Gene Expression ; Humans ; Imatinib Mesylate - therapeutic use ; Nitriles ; Oncogene Proteins, Fusion - genetics ; Oncogene Proteins, Fusion - metabolism ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality ; Prognosis ; Pyrazoles - therapeutic use ; Pyrimidines ; Review ; Survival Analysis ; Translocation, Genetic
É parte de: Haematologica (Roma), 2016-04, Vol.101 (4), p.407-416
Descrição: Acute lymphoblastic leukemia (ALL) is a heterogeneous disease at the genetic level. Chromosomal abnormalities are used as diagnostic, prognostic and predictive biomarkers to provide subtype, outcome and drug response information. t(12;21)/ETV6-RUNX1 and high hyper-diploidy are good-risk prognostic biomarkers whereas KMT2A(MLL) translocations, t(17;19)/TCF3-HLF, haploidy or low hypodiploidy are high-risk biomarkers. t(9;22)/BCR-ABL1 patients require targeted treatment (imatinib/dasatinib), whereas iAMP21 patients achieve better outcomes when treated intensively. High-risk genetic biomarkers are four times more prevalent in adults compared to children. The application of genomic technologies to cases without an established abnormality (B-other) reveals copy number alterations which can be used either individually or in combination as prognostic biomarkers. Transcriptome sequencing studies have identified a network of fusion genes involving kinase genes -ABL1,ABL2,PDGFRB,CSF1R,CRLF2,JAK2 and EPOR in-vitro and in-vivo studies along with emerging clinical observations indicate that patients with a kinase-activating aberration may respond to treatment with small molecular inhibitors like imatinib/dasatinib and ruxolitinib. Further work is required to determine the true frequency of these abnormalities across the age spectrum and the optimal way to incorporate such inhibitors into protocols. In conclusion, genetic biomarkers are playing an increasingly important role in the management of patients with ALL.
Editor: Italy: Ferrata Storti Foundation
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 6 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia

Moorman, Anthony V

Italy: Ferrata Storti Foundation

Buscando em bases de dados remotas. Favor aguardar.